Argenx Se (ARGX) Non-Current Deferred Tax Liability (2020 - 2024)
Argenx Se (ARGX) posted Non-Current Deferred Tax Liability of $5.0 million for Q2 2024, down 3.12% on a QoQ basis from $5.2 million in Q4 2023, and down 43.85% year-over-year from $8.9 million in Q3 2023.
Argenx Se (ARGX) Non-Current Deferred Tax Liability (2020 - 2024) Analysis & Trends
Argenx Se's Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $5.0 million for Q2 2024.
- Quarterly Non-Current Deferred Tax Liability fell 43.85% year-over-year to $5.0 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $5.0 million (down 43.85% YoY) and the FY2023 annual result came in at $5.2 million, down 38.67% from the prior year.
- Non-Current Deferred Tax Liability was $5.0 million for Q2 2024 at Argenx Se, down from $5.2 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $12.4 million in Q2 2021 and bottomed at $959371.8 in Q2 2020.
- A 5-year average of $6.3 million and a median of $6.4 million in 2021 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability soared 1191.26% — and 2024, when it plunged 43.85%.
- Argenx Se's Non-Current Deferred Tax Liability stood at $1.4 million in 2020, then soared by 345.52% to $6.4 million in 2021, then soared by 30.57% to $8.4 million in 2022, then plunged by 38.67% to $5.2 million in 2023, then declined by 3.12% to $5.0 million in 2024.
- Business Quant data shows ARGX's Non-Current Deferred Tax Liability at $5.0 million in Q2 2024, $5.2 million in Q4 2023, and $8.9 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 4.99 Mn |
| Jun 30, 2024 | 4.99 Mn |
| Dec 31, 2023 | 5.16 Mn |
| Dec 31, 2023 | 5.16 Mn |
| Jun 30, 2023 | 8.89 Mn |
| Jun 30, 2023 | 8.89 Mn |
| Dec 31, 2022 | 8.41 Mn |
| Dec 31, 2022 | 8.41 Mn |
| Jun 30, 2022 | 7.66 Mn |
| Jun 30, 2022 | 7.66 Mn |
| Dec 31, 2021 | 6.44 Mn |
| Dec 31, 2021 | 6.44 Mn |
| Jun 30, 2021 | 12.39 Mn |
| Jun 30, 2021 | 12.39 Mn |
| Dec 31, 2020 | 1.45 Mn |
| Dec 31, 2020 | 1.45 Mn |
| Jun 30, 2020 | 959,371.77 |
| Jun 30, 2020 | 959,371.77 |